UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Quest Diagnostics Incorporated $DGX

Key Points

• UBS Asset Management increased its Quest Diagnostics position by 11.3% in the second quarter, adding 95,804 shares to hold 942,407 shares worth approximately $199.7 million. Institutional investors collectively own 88.06% of the company.
• Quest Diagnostics beat quarterly expectations, reporting $3.12 in EPS and $3.04 billion in revenue, with revenue up 10.2% year over year. The company reaffirmed fiscal 2026 EPS guidance of $11.05–$11.25.
• Analysts give the stock a consensus “Moderate Buy” rating with a $235.31 target price, while Quest declared a quarterly dividend of $0.86 per share, implying a 1.4% yield.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 11.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 942,407 shares of the medical research company's stock after purchasing an additional 95,804 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.85% of Quest Diagnostics worth $199,743,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Bank OZK purchased a new stake in shares of Quest Diagnostics during the 2nd quarter worth approximately $3,247,000. ANTIPODES PARTNERS Ltd grew its position in shares of Quest Diagnostics by 178.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company's stock valued at $29,847,000 after buying an additional 110,280 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Quest Diagnostics by 39.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company's stock valued at $3,265,000 after buying an additional 4,334 shares during the last quarter. BlackRock Inc. acquired a new stake in Quest Diagnostics during the 2nd quarter worth $1,965,923,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of Quest Diagnostics during the fourth quarter worth about $92,000. Hedge funds and other institutional investors own 88.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Jefferies Financial Group reissued a "buy" rating and issued a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Truist Financial lifted their price target on Quest Diagnostics from $225.00 to $250.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Wall Street Zen upgraded Quest Diagnostics from a "hold" rating to a "buy" rating in a research note on Tuesday, July 28th. UBS Group increased their price objective on Quest Diagnostics from $220.00 to $232.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Finally, Argus set a $260.00 target price on shares of Quest Diagnostics in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $235.31.

Quest Diagnostics Stock Performance

NYSE DGX opened at $240.96 on Tuesday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. Quest Diagnostics Incorporated has a 52-week low of $171.18 and a 52-week high of $247.19. The business's 50-day moving average price is $224.91 and its 200 day moving average price is $207.46. The firm has a market cap of $26.59 billion, a P/E ratio of 25.58, a P/E/G ratio of 2.24 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the prior year, the business earned $2.62 EPS. The firm's revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities research analysts expect that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics's dividend payout ratio is 36.52%.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark E. Delaney sold 1,600 shares of the business's stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president directly owned 10,335 shares of the company's stock, valued at approximately $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael E. Prevoznik sold 22,677 shares of the company's stock in a transaction on Friday, August 28th. The stock was sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the transaction, the senior vice president owned 37,557 shares of the company's stock, valued at approximately $9,130,482.27. The trade was a 37.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,424 shares of company stock worth $7,518,693 over the last 90 days. 0.88% of the stock is currently owned by insiders.

Quest Diagnostics Company Profile

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source